Completed PHASE2 INTERVENTIONAL NCT00257023

An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia

Exploratory Study of Paliperidone in Patients With Schizophrenia to Investigate the Safety and Efficacy

Sponsor: Janssen Pharmaceutical K.K.

Updated 5 times since 2017 Last updated: May 16, 2011 Started: Feb 28, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Janssen Pharmaceutical K.K. and has accumulated 5 data snapshots since 2005. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutical K.K.

Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.